Patent Struggles Could Determine Japanese iPS Cell Work
This article was originally published in PharmAsia News
Executive Summary
The future of Japanese research and development of induced pluripotent stem cells could be determined by a possible patent competition. Bayer Yakuhin, the Japanese subsidiary of German's Bayer AG, says its researchers created iPS cells from human cells before a Kyoto University team, which announced its "breakthrough" work last November. In addition to Japanese researchers, the University of Wisconsin also has claimed success in creating iPS cells from human cells at the same time as the Kyoto University team. (Click here for more - a subscription may be required
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.